Matthew L Greene

US Patent:

20220249382, Aug 11, 2022

Filed:

Apr 22, 2022

Appl. No.:

17/727510

Inventors:

- Encino CA, US
Matthew Davidson - Encino CA, US
Johan Oscar Lennart Andreasson - Redwood City CA, US
Michael David Favero - Tampa FL, US
Matthew Benjamin Greene - Tampa FL, US

International Classification:

A61K 9/20
A61K 31/404

Abstract:

Compositions comprising an AhR agonist compound, such as indigo and/or an indigo derivative, such as indirubin and isatin, are described. Methods of treatment, including the treatment of ulcerative colitis, by administering the compositions are described. In an embodiment, compositions in the form of a solid amorphous dispersion of the AhR agonist are described.

US Patent:

20200345645, Nov 5, 2020

Filed:

May 1, 2020

Appl. No.:

16/865183

Inventors:

- Encino CA, US
Matthew Davidson - Encino CA, US
Johan Oscar Lennart Andreasson - Redwood City CA, US
Michael David Favero - Tampa FL, US
Matthew Benjamin Greene - Tampa FL, US

International Classification:

A61K 9/20
A61K 31/404

Abstract:

Compositions comprising an AhR agonist compound, such as indigo and/or an indigo derivative, such as indirubin and isatin, are described. Methods of treatment, including the treatment of ulcerative colitis, by administering the compositions are described. In an embodiment, compositions in the form of a solid amorphous dispersion of the AhR agonist are described.

US Patent:

20200345691, Nov 5, 2020

Filed:

Jun 3, 2020

Appl. No.:

16/891586

Inventors:

- Encino CA, US
Matthew Davidson - Encino CA, US
Johan Oscar Lennart Andreasson - Redwood City CA, US
Michael David Favero - Tampa FL, US
Matthew Benjamin Greene - Tampa FL, US

International Classification:

A61K 31/404
A61K 47/32
A61K 47/38
A61K 9/10
A61P 1/04

Abstract:

Compositions comprising an AhR agonist compound, such as indigo and/or an indigo derivative, such as indirubin and isatin, are described. Methods of treatment, including the treatment of ulcerative colitis, by administering the compositions are described. In an embodiment, compositions in the form of a solid amorphous dispersion of the AhR agonist are described.

US Patent:

20200253877, Aug 13, 2020

Filed:

Oct 17, 2019

Appl. No.:

16/656180

Inventors:

- Boston MA, US
Charles Larry BISGAIER - Ann Arbor MI, US
Matthew Benjamin GREENE - Tampa FL, US

International Classification:

A61K 9/20
A61K 31/194
A61P 9/10
A61K 9/28

Abstract:

This invention provides tablets comprising gemcabene calcium salt hydrate Crystal Form 2 or gemcabene calcium salt hydrate Crystal Form C3, each having a PSD90 ranging from 35 μm to 90 μm as measured by laser light diffraction and wherein the tablet has a gemcabene dissolution profile characterized by a % dissolution profile of at least 80% in pH 5.0 potassium acetate buffer at 37 C.0.5 C. in no more than 45 minutes as measured by ultra-violet/visible light absorption using a detection wavelength range of 216 nm to 230 nm. This invention further provides gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6. The tablets and gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6 are useful for treating or preventing liver disease or an abnormal liver condition, a disorder of lipoprotein or glucose metabolism, a cardiovascular or related vascular disorder, a disease caused by fibrosis (such as liver fibrosis), or a disease associated with inflammation (such as liver inflammation).

US Patent:

20190008779, Jan 10, 2019

Filed:

May 11, 2018

Appl. No.:

15/977226

Inventors:

- Livonia MI, US
Charles Larry Bisgaier - Ann Arbor MI, US
Janice Cacace - St. Petersburg FL, US
Matthew Benjamin Greene - Tampa FL, US

International Classification:

A61K 9/28
A61K 31/40
A61K 31/194
A61K 9/48

Abstract:

The present invention provides pharmaceutical compositions comprising a statin and an outer coating, and optionally gemcabene, and methods of use thereof.

US Patent:

20160303077, Oct 20, 2016

Filed:

Dec 9, 2014

Appl. No.:

15/102949

Inventors:

- Cambridge MA, US
Brian MCMILLAN - Clearwater FL, US
Matthew GREENE - Clearwater FL, US
Walter PISKORSKI - Nashua NH, US

International Classification:

A61K 31/403
A61K 9/20

Abstract:

Provided are pharmaceutical compositions comprising (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form. The compositions are formulated for providing a sustained release of enantiomerically pure (1R,5S)-1-(naphthalene-2-yl)-3-azabicyclo[3.1.0]hexane. The compositions are substantially free of the other (−) enantiomer of the compound.